LLS, partners commit $4.5M for blood cancer patients impacted by COVID-19

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Leukemia & Lymphoma Society and its partners developed the LLS COVID-19 Patient Financial Aid Program to provide $250 for eligible blood cancer patients struggling with the economic hardship because of COVID-19.

Amgen, Inc., Bristol Myers Squibb Foundation, Foundation Medicine, Inc., Genentech, a member of the Roche Group, Incyte, MorphoSys Foundation, Servier Pharmaceuticals, Subaru of America, Inc., and Takeda Oncology are contributing to the program.

“Along with our partners, we anticipated that blood cancer patients would need help with non-medical expenses such as food and other household needs, and housing and transportation,” Louis J. DeGennaro, LLS president and CEO, said in a statement. “And we aim to raise up to $10 million to help even more patients during this crisis.”

LLS is providing free educational resources and support to patients through a series of blogs, webinars and chats led by medical professionals.

LLS is soliciting donations for the program. All donations contribute to LLS’s mission to find cures for blood cancers and to ensure patient access to care.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login